Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Xencor to Present at Upcoming Investor Conferences


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences:

  • TD Cowen 44th Annual Health Care Conference
    Date: Wednesday, March 6, 2024
    Presentation Time: 12:50 p.m. ET / 9:50 a.m. PT
    Location: Boston

  • Leerink Partners Global Biopharma Conference
    Date: Tuesday, March 12, 2024
    Presentation Date/Time: Wednesday, March 13, 2024, 9:20 a.m. ET / 6:20 a.m. PT
    Location: Miami

  • Jefferies Biotech on the Bay Summit
    Date: Wednesday, March 13, 2024
    Location: Miami

  • Barclays Global Healthcare Conference
    Date: Thursday, March 14, 2024
    Presentation Time: 11:15 a.m. ET / 8:15 a.m. PT
    Location: Miami

Live webcasts of the Cowen, Leerink and Barclays presentations will be available under “Events Presentations” in the Investors section of the Company’s website located at www.xencor.com. Replays of the events will be available on the Xencor website for at least 30 days following the presentations.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240228121602/en/

Xencor Inc. Aktie

18,70 €
2,23 %
Aufwärts geht es heute für die Xencor Inc. Aktie mit einem Gewinn von 2,23 %.
Des weiteren hat Xencor Inc. derzeit 9 Buy-Einschätzungen und 1 Sell-Einschätzungen durch unsere Community zu Buche stehen.
Ein Kursziel von 31 € für Xencor Inc. würde eine Steigerung von mehr als 50% gegenüber dem aktuellen Kurs von 18.7 € bedeuten.
Like: 0
Teilen
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Rechtlicher Hinweis

Kommentare